Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance

被引：23

作者：

Schwartzberg, Lee S. ^{[1
]}

Horinouchi, Hidehito ^{[2
]}

Chan, David ^{[3
]}

Chernilo, Sara ^{[4
]}

Tsai, Michaela L. ^{[5
]}

Isla, Dolores ^{[6
]}

Escriu, Carles ^{[7
]}

Bennett, John P. ^{[8
]}

Clark-Langone, Kim ^{[8
]}

Svedman, Christer ^{[8
]}

Tomasini, Pascale ^{[9
,10
]}

机构：

[1] West Canc Ctr & Res Inst, 7945 Wolf River Blvd, Germantown, TN 38138 USA

[2] Natl Canc Ctr, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan

[3] Canc Care Associates TMPN, 3285 Skypk Dr, Torrance, CA 90505 USA

[4] Inst Nacl Torax, Jose Manuel Infante 717, Santiago 7500691, Chile

[5] Virginia Piper Canc Inst, Minnesota Oncol, 800 E 28th St,Suite 602, Minneapolis, MN 55407 USA

[6] Univ Hosp Lozano Blesa, Avda S Juan Bosco 15, Zaragoza 50009, Spain

[7] Clatterbridge Canc Ctr, Clatterbridge Rd, Wirral CH63 4JK, Merseyside, England

[8] Genom Hlth Inc, 301 Penobscot Dr, Redwood City, CA 94063 USA

[9] Aix Marseille Univ, AP HP, Inserm UMR1068, CNRS,UMR7258,UM105, Marseille, France

[10] Aix Marseille Univ, Ctr Rech Cancerol Marseille, Inserm UMR1068, CNRS,UMR7258,UM105, Marseille, France

来源：

NPJ PRECISION ONCOLOGY | 2020年 / 4卷 / 01期

关键词：

CIRCULATING TUMOR DNA; EGFR MUTATION; PHASE-III; NSCLC; PLASMA; RESISTANCE; ERLOTINIB; CRIZOTINIB; PREDICTOR; EVOLUTION;

D O I：

10.1038/s41698-020-0118-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Molecular testing for genomic variants is recommended in advanced non-small cell lung cancer (NSCLC). Standard tissue biopsy is sometimes infeasible, procedurally risky, or insufficient in tumor tissue quantity. We present the analytical validation and concordance study ofEGFRvariants using a new 17-gene liquid biopsy assay (NCT02762877). Of 144 patients enrolled with newly diagnosed or progressive stage IV nonsquamous NSCLC, 140 (97%) had liquid assay results, and 117 (81%) had bothEGFRblood and tissue results. Alterations were detected in 58% of liquid samples. Overall tissue-liquid concordance forEGFRalterations was 94.0% (95% CI 88.1%, 97.6%) with positive percent agreement of 76.7% (57.7%, 90.1%) and negative percent agreement of 100% (95.8%, 100%). Concordance forALKstructural variants was 95.7% (90.1%, 98.6%). This assay detected alterations in other therapeutically relevant genes at a rate similar to tissue analysis. These results demonstrate the analytical and clinical validity of this 17-gene assay.

引用

页数：7

共 45 条

[1] Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS) [J].

Al-Kateb, Hussam ;

Nguyen, TuDung T. ;

Steger-May, Karen ;

Pfeifer, John D. .

MOLECULAR ONCOLOGY, 2015, 9 (09) :1737-1743

[2]

[Anonymous], NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) with NCCN Evidence Blocks&TRADE

[3]

[Anonymous], 2005, PLOS MED

[4] Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies [J].

Bettegowda, Chetan ;

Sausen, Mark ;

Leary, Rebecca J. ;

Kinde, Isaac ;

Wang, Yuxuan ;

Agrawal, Nishant ;

Bartlett, Bjarne R. ;

Wang, Hao ;

Luber, Brandon ;

Alani, Rhoda M. ;

Antonarakis, Emmanuel S. ;

Azad, Nilofer S. ;

Bardelli, Alberto ;

Brem, Henry ;

Cameron, John L. ;

Lee, Clarence C. ;

Fecher, Leslie A. ;

Gallia, Gary L. ;

Gibbs, Peter ;

Le, Dung ;

Giuntoli, Robert L. ;

Goggins, Michael ;

Hogarty, Michael D. ;

Holdhoff, Matthias ;

Hong, Seung-Mo ;

Jiao, Yuchen ;

Juhl, Hartmut H. ;

Kim, Jenny J. ;

Siravegna, Giulia ;

Laheru, Daniel A. ;

Lauricella, Calogero ;

Lim, Michael ;

Lipson, Evan J. ;

Marie, Suely Kazue Nagahashi ;

Netto, George J. ;

Oliner, Kelly S. ;

Olivi, Alessandro ;

Olsson, Louise ;

Riggins, Gregory J. ;

Sartore-Bianchi, Andrea ;

Schmidt, Kerstin ;

Shih, Ie-Ming ;

Oba-Shinjo, Sueli Mieko ;

Siena, Salvatore ;

Theodorescu, Dan ;

Tie, Jeanne ;

Harkins, Timothy T. ;

Veronese, Silvio ;

Wang, Tian-Li ;

Weingart, Jon D. .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)

[5]

Centers for Medicare & Medicaid Services, 2017, FDA ANN APPR CMS PRO

[6] FDA drug approval summary:: Gefitinib (ZD1839) (Iressa®) tablets [J].

Cohen, MH ;

Williams, GA ;

Sridhara, R ;

Chen, G ;

Pazdur, R .

ONCOLOGIST, 2003, 8 (04) :303-306

[7] Spatial and temporal diversity in genomic instability processes defines lung cancer evolution [J].

de Bruin, Elza C. ;

McGranahan, Nicholas ;

Mitter, Richard ;

Salm, Max ;

Wedge, David C. ;

Yates, Lucy ;

Jamal-Hanjani, Mariam ;

Shafi, Seema ;

Murugaesu, Nirupa ;

Rowan, Andrew J. ;

Groenroos, Eva ;

Muhammad, Madiha A. ;

Horswell, Stuart ;

Gerlinger, Marco ;

Varela, Ignacio ;

Jones, David ;

Marshall, John ;

Voet, Thierry ;

Van Loo, Peter ;

Rassl, Doris M. ;

Rintoul, Robert C. ;

Janes, Sam M. ;

Lee, Siow-Ming ;

Forster, Martin ;

Ahmad, Tanya ;

Lawrence, David ;

Falzon, Mary ;

Capitanio, Arrigo ;

Harkins, Timothy T. ;

Lee, Clarence C. ;

Tom, Warren ;

Teefe, Enock ;

Chen, Shann-Ching ;

Begum, Sharmin ;

Rabinowitz, Adam ;

Phillimore, Benjamin ;

Spencer-Dene, Bradley ;

Stamp, Gordon ;

Szallasi, Zoltan ;

Matthews, Nik ;

Stewart, Aengus ;

Campbell, Peter ;

Swanton, Charles .

SCIENCE, 2014, 346 (6206) :251-256

[8] Gefitinib Treatment in EGFR Mutated Caucasian NSCLC Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status [J].

Douillard, Jean-Yves ;

Ostoros, Gyula ;

Cobo, Manuel ;

Ciuleanu, Tudor ;

Cole, Rebecca ;

McWalter, Gael ;

Walker, Jill ;

Dearden, Simon ;

Webster, Alan ;

Milenkova, Tsveta ;

McCormack, Rose .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) :1345-1353

[9] Afatinib: First Global Approval [J].

Dungo, Rosselle T. ;

Keating, Gillian M. .

DRUGS, 2013, 73 (13) :1503-1515

[10]

Food and Drug Administration, 2007, STAT GUID REP RES ST

← 1 2 3 4 5 →